Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)
The Asia Group (TAG) has released an update to its 2023 white paper “Observations on Drug Pricing and Innovation in Japan” which analyzes the outstanding policy challenge of the “zero co-factor” rule under the cost-based price calculation method, which continues to undermine the Japanese government’s efforts to restore the country’s drug discovery capabilities and create a robust pharmaceutical industry ecosystem.